Kailera Therapeutics, Inc (KLRA)., a portfolio company of London-listed RTW Biotech Opportunities Ltd, completed a $625 million initial public offering that set a record as the largest-ever biotech IPO by proceeds, RTW Bio said on Monday.
The company said that the IPO was upsized from $500 million, with 39 million shares priced at $16 each. That valuation marked a 47 percent increase from RTW Bio's carrying value as of March 31 and a 49 percent gain on cost.
Kailera began trading on the Nasdaq under ticker 'KLRA' on April 17. Shares closed the first day up 62.5 percent at $26, pushing the valuation uplift to 139 percent versus RTW Bio's March 31 holding value and 143 percent versus cost.
Before the IPO, Kailera made up 3.5 percent of RTW Bio's NAV.
RTW Bio said the deal underscores two parts of its strategy: its "newco creation" model and the value in its private portfolio. RTW Investments co-led Kailera's 2024 Series A with Bain Capital Life Sciences. As of March 31, 24 percent of RTW Bio's NAV was allocated to private investments, including Kailera.
On the Nasdaq, shares of Kailera were losing 0.04 percent after hours at $25.99, after closing Friday's regular trading 62.50 percent higher at $26.00
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.